Genmab AS

Genmab AS Financial Leverage

The Financial Leverage (Equity Multiplier) of Genmab AS (GMAB) as of Nov 22, 2026 is 2.20. In the previous year, Financial Leverage (Equity Multiplier) was 1.25 — a change of 76.36% (higher).

Financial Leverage

2.20

YoY

76.36%

Last updated:

Financial Leverage (Equity Multiplier) of Genmab AS is 2025 2.20 . Financial Leverage (Equity Multiplier) of Genmab AS was 2024 1.25 . It decreases by 76.36% higher compared to the previous year.

The Genmab AS Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.06 USD
Jan 1, 2019
1.08 USD
Jan 1, 2020
1.11 USD
Jan 1, 2021
1.11 USD
Jan 1, 2022
1.10 USD
Jan 1, 2023
1.12 USD
Jan 1, 2024
1.25 USD
Jan 1, 2025
2.20 USD
The Genmab AS Financial Leverage history
YEARFinancial LeverageYoY
2.20+76.36%
1.25+11.82%
1.12+1.12%
1.10-0.50%
1.11+0.34%
1.11+2.57%
1.08+2.11%
1.06+0.28%
1.05-3.00%
1.09-3.04%
1.12-20.63%
1.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

Financial Leverage (Equity Multiplier) of Genmab AS is 2.20 in 2025.

Financial Leverage (Equity Multiplier) of Genmab AS changed from 1.25 to 2.20, representing a 76.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Genmab AS since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Genmab AS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genmab AS

All Key Metrics — Genmab AS